IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells. - Wikidata - wikimedia - TriplyDB

IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells.

IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells.

http://www.wikidata.org/entity/Q34636880

about

Role of the tumor microenvironment in mature B-cell lymphoid malignancies Chronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted Agents Pharmacological targeting of PI3K isoforms as a therapeutic strategy in chronic lymphocytic leukaemia Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma Targeted therapies in CLL: mechanisms of resistance and strategies for management Targeting neoplastic B cells and harnessing microenvironment: the "double face" of ibrutinib and idelalisib Secondary mutations as mediators of resistance to targeted therapy in leukemia Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib.Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab Targeting phosphatidylinositol-3-kinase pathway for the treatment of Philadelphia-negative myeloproliferative neoplasms.The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL.Idelalisib therapy of indolent B-cell malignancies: chronic lymphocytic leukemia and small lymphocytic or follicular lymphomas Targeting PI3Kδ and PI3Kγ signalling disrupts human AML survival and bone marrow stromal cell mediated protection.Factors involved in CLL pathogenesis and cell survival are disrupted by differentiation of CLL B-cells into antibody-secreting cells.Targeted therapy for chronic lymphocytic leukemia: current status and future directions.Emerging immunological drugs for chronic lymphocytic leukemia.Pharmacodynamic considerations of small molecule targeted therapy for treating B-cell malignancies in the elderly.Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment.New drug discovery approaches targeting recurrent mutations in chronic lymphocytic leukemia.Phosphatidylinositol 3-kinase δ blockade increases genomic instability in B cells Targeting the mTOR Pathway in Leukemia.Genetic aberrations in small B-cell lymphomas and leukemias: molecular pathology, clinical relevance and therapeutic targets.Paving the way for new agents; is standard chemotherapy part of the treatment paradigm for chronic lymphocytic leukemia in the future?Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells.How I manage ibrutinib-refractory chronic lymphocytic leukemia.Duvelisib: a phosphoinositide-3 kinase δ/γ inhibitor for chronic lymphocytic leukemia.The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells.PI3Kδ-selective and PI3Kα/δ-combinatorial inhibitors in clinical development for B-cell non-Hodgkin lymphoma.Recent therapeutic advances in chronic lymphocytic leukemia.Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia.Combination therapy with the type II anti-CD20 antibody obinutuzumab.Distinct roles for phosphoinositide 3-kinases γ and δ in malignant B cell migration.Antitumor effects of duvelisib on Epstein-Barr virus-associated lymphoma cells.Identification of potential ibrutinib combinations in hematological malignancies using a combination high-throughput screen.Duvelisib, an oral dual PI3K-δ, γ inhibitor, shows clinical activity in indolent non-Hodgkin lymphoma in a phase 1 study Copanlisib for treatment of B-cell malignancies: the development of a PI3K inhibitor with considerable differences to idelalisib

P2860

Q26748775-BA63E1E2-C5F5-4113-BD0B-2FB0EFEFA19B Q26764833-1818EF4A-97FD-4BB7-BE05-1D46E87F3233 Q26779129-AC9E02E5-A6A2-4851-91FA-7702C053EC93 Q26865645-E4E2B40B-D17F-4348-8326-F639E3DD2197 Q27002528-9EBB6330-35B9-4FBA-B015-AEC495185DC5 Q27025812-D03513B2-D692-4A82-8176-925A2C985B62 Q28087213-C10FB4FB-3A50-45AE-987B-AC5099A8DEBA Q30252869-1F9E65DB-1FC6-4FF5-B2FB-7665015A41A0 Q35076449-1AEBE218-7C26-443B-A112-76B51FFFED54 Q35727453-6691D890-76DE-458B-81B7-AAAAEC8F4ECE Q36021849-D939A2B1-55FA-4E6B-9000-EDCCB5910422 Q37058203-EF7C0263-9FCD-4093-BFD9-BBE13DF7D439 Q37457673-5FAA3C1A-AC86-4CD9-8E1B-D507E6B179F5 Q38298483-3EE2A3FA-F79F-4C78-A294-799BD7043592 Q38331701-794BC76F-F7AB-407A-880D-75AAD2EEC622 Q38543771-DB5A27EE-F9C9-4F76-BD41-9985A0FBB749 Q38544216-4D6F17A0-695A-4529-9BD3-6673F9B24FEF Q38550810-663BDB4C-D0AF-4428-81E8-F945758F645C Q38646974-AC53117E-B8F1-471D-B638-F687ABD63BBA Q38716411-485BCEA0-FD53-486F-8EBB-2E3B600E7015 Q38790630-B9AFA317-3012-4828-B81E-BA8B4A3B6588 Q38819164-A76D3401-1259-4CD8-9B4C-910FE11DFFB9 Q38851368-1181D807-7E69-44E5-8914-3C67B2B1939D Q38882332-81B1086D-5F89-44CA-B8A4-EB3BD866A769 Q39016282-E03AE8C2-4EFC-4918-8A05-1859F18D160A Q39226787-4A5244B1-CFB9-42DB-B741-9355ED5F71D2 Q40575812-84727F9B-1626-4C7D-B7B9-B80862C5270B Q41994564-B874C546-AFD5-4440-BF89-0C4795B0729A Q46318389-DD500BEE-CD45-4ABB-8E8C-0968DA044B42 Q47754054-EC46667A-885A-4635-BCFC-96B88E6C2668 Q47898168-53F0D862-474E-4AC1-BE92-AC678E337129 Q51738230-0CB4A630-822A-4095-8F1D-608F7A3CA90F Q52664561-AE20CE75-BFB0-4424-B450-143D94E8598C Q54990441-231A4C23-21E6-4E69-AE92-D1828384850D Q58697794-3D733EA3-8A3F-40CF-80AF-799295F0C069 Q58729853-48E54D80-D7B9-48DA-80B6-62A1382EE6B5

P2860

IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells.

http://www.wikidata.org/entity/Q34636880

description

2014 nî lūn-bûn

@nan

2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

IPI-145 antagonizes intrinsic ...... ic lymphocytic leukemia cells.

@ast

IPI-145 antagonizes intrinsic ...... ic lymphocytic leukemia cells.

@en

IPI-145 antagonizes intrinsic ...... ic lymphocytic leukemia cells.

@nl

type

label

IPI-145 antagonizes intrinsic ...... ic lymphocytic leukemia cells.

@ast

IPI-145 antagonizes intrinsic ...... ic lymphocytic leukemia cells.

@en

IPI-145 antagonizes intrinsic ...... ic lymphocytic leukemia cells.

@nl

prefLabel

IPI-145 antagonizes intrinsic ...... ic lymphocytic leukemia cells.

@ast

IPI-145 antagonizes intrinsic ...... ic lymphocytic leukemia cells.

@en

IPI-145 antagonizes intrinsic ...... ic lymphocytic leukemia cells.

@nl

P1433

Q34636880-ADAEFBEC-62C8-492B-95BD-F5582052A06F

P1476

Q34636880-1E43EF97-E947-452C-B4F0-7219ED5BBDE2

P2093

Q34636880-0BEF126F-621B-4D29-9376-35EA96DDA334

Q34636880-2A6C792E-6C83-403C-9289-3054FED5A801

Q34636880-6C0798D1-4119-46E8-8476-4BAB0F856C6B

Q34636880-8E2D3853-CB48-4441-8A58-A6894A80DF3D

Q34636880-A66E44AD-2B31-48BA-81D3-00A182229A81

Q34636880-AAF0E403-2568-466C-96E0-CDF36B59271A

Q34636880-CE3F7EDD-A24C-43C1-AE62-44DEC7A0EE42

Q34636880-FF281BC8-295F-4489-8CC0-85DCF9C09EDE

P2860

Q34636880-0E90E01D-5499-46A7-B227-9223D950A3E2

Q34636880-34FECCC2-D484-4994-B91D-3F6EAAF0C817

Q34636880-5C7619E6-8659-45A1-AA7C-850BD16710B9

Q34636880-61DDC1D7-347D-4D15-BE9E-CC73FA0B00FC

Q34636880-695BD389-744C-4DD9-BC6E-58C14609B75F

Q34636880-98DCD831-60BD-4915-9C53-EFB647C59B24

Q34636880-9CFB3010-045D-4FE2-ADD8-45B085AE6A2E

Q34636880-A5A7F99C-E84A-42E6-8294-EAE5FC8A556F

Q34636880-C4F1F21D-A642-422A-B693-8786C5A1F203

Q34636880-CD03C2A3-1D68-4634-9057-5AD6B3B4FFCF

P304

Q34636880-675B1594-3610-4F68-A31B-7F3C2DBDEE84

P31

Q34636880-0497A4A6-B4F8-46CC-863E-F7A06F7B8B8F

P356

Q34636880-A1758F69-36FB-4F37-B2FF-8FD9B4D68094

P407

Q34636880-09FB6A4F-7FF5-4102-AC0B-7037A2CA09F7

P433

Q34636880-8F75C916-5CC7-4A36-9258-123C215309DE

P478

Q34636880-EE99B23C-E35F-41B7-B73E-9802A02E930B

P50

Q34636880-58A2CB0C-AC5F-43A3-9ED5-88927C435D6F

P577

Q34636880-2964167A-D605-4B05-9D9F-8FECBB7C1E7A

P5875

Q34636880-2188DFA2-376F-40F8-8A59-753E896C5186

P698

Q34636880-7707D52D-D2AB-459F-AA44-36031049827B

P921

Q34636880-478615DB-9F4E-4FDF-BE7F-A645147566CC

Q34636880-59997681-FEB4-4ACC-B663-D7EE1270A044

P932

Q34636880-53131933-E091-4361-A1A0-BF309E1DED23

P356

BLOOD-2014-07-587279

P1433

P1476

IPI-145 antagonizes intrinsic ...... ic lymphocytic leukemia cells.

@en

P2093

Amy J Johnson

http://www.w3.org/2001/XMLSchema#string

Amy Lehman

http://www.w3.org/2001/XMLSchema#string

Daphne Guinn

http://www.w3.org/2001/XMLSchema#string

Jason A Dubovsky

http://www.w3.org/2001/XMLSchema#string

Jeffery Kutok

http://www.w3.org/2001/XMLSchema#string

Jennifer A Woyach

http://www.w3.org/2001/XMLSchema#string

Shuai Dong

http://www.w3.org/2001/XMLSchema#string

Yiming Zhong

http://www.w3.org/2001/XMLSchema#string

P2860

Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals

Characterization of a new chronic lymphocytic leukemia cell line for mechanistic in vitro and in vivo studies relevant to disease

Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.

Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.

The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia.

The B-cell receptor signaling pathway as a therapeutic target in CLL.

PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models.

P304

3583-3586

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2014-07-587279

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

124

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-09-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

266254393

http://www.w3.org/2001/XMLSchema#string

P698

25258342

http://www.w3.org/2001/XMLSchema#string

P921

P932

4256910

http://www.w3.org/2001/XMLSchema#string